GO
Loading...

Enter multiple symbols separated by commas

Biotech and Pharmaceuticals Medicine

More

  • Chantix Ad

    While thumbing through “Parade” magazine yesterday, the fluffy publication that you find tucked inside some Sunday newspapers, I noticed an ad for Pfizer’s stop-smoking drug Chantix. It caught my eye because the company had stopped doing what’s called “branded” advertising for the pill earlier this year because of new safety concerns...

  • Former Merck CEO Prodding Industry On Drug Pricing Thursday, 1 May 2008 | 10:31 AM ET
    Dr. Vagelos

    I didn't post yesterday because I was in Philadelphia shooting a story for an upcoming episode of "The Business of Innovation" on CNBC. It's a piece about big pharma and we went to Philly to interview the still very busy former CEO of Merck (two CEOs ago), Dr. Roy Vagelos.

  • Merck "Adapts" To Tredaptive Setback Tuesday, 29 Apr 2008 | 11:37 AM ET
    merck_HQ2.jpg

    Investors are finding no solace in Merck's reaffirmation that it'll still hit its earnings numbers this year. Instead they're punishing the stock after the company announced what everyone is calling a surprise and a significant setback.

  • Regulatory "Risky Business" for Pharma & Biotech Monday, 28 Apr 2008 | 11:56 AM ET
    Risky Business

    It's a big day for pipeline progress...or not. Late Friday, Merck and Schering-Plough announced that the Food and Drug Administration won't approve their combo Claritin-Singulair combo pill for allergies.

  • Amgen: Is "A" For Anemia Or Acquisition? Friday, 25 Apr 2008 | 12:35 PM ET
    AMGEN

    The morning after Amgen reported its first quarter earnings my inbox runneth over with analyst research reports on the biotech behemoth. The company beat the Street by eight cents a share. But the focus remains on the anemia drug franchise.

  • Pfizer's Kindler Doesn't Duck Tough Questions Thursday, 24 Apr 2008 | 1:55 PM ET
    Jeff Kindler, Pfizer Chairman and CEO

    Pfizer held its shareholder meeting Thursday morning at the historic Memphis hotel where the ducks march through the lobby. I haven't seen the spectacle yet, but I'm told it's quite the scene. Watch my exclusive interview with Chairman and CEO Jeff Kindler.

  • AstraZeneca Raises Guidance, Quarterly Sales Light Thursday, 24 Apr 2008 | 7:11 AM ET

    AstraZeneca nudged up its forecast for 2008 earnings on Thursday, but sales of key products in the first quarter were weaker than hoped for, knocking its shares.

  • Schering Plows Through Vytorin Firestorm Wednesday, 23 Apr 2008 | 12:57 PM ET
    schering_plough_earnings.jpg

    Schering-Plough beat the Street by a surprising 16 cents per share and the beaten-down shares are rallying. In an exclusive CNBC interview Wednesday morning, Chairman and CEO Fred Hassan explained how the company was able to blow away estimates...

  • Halftime Report: Da Bears Are Winning Tuesday, 22 Apr 2008 | 12:41 PM ET

    This halftime report is not brought to you by (pick your prescription drug). So, we're pretty much at the midway point of big pharma's earnings season and Goldman Sachs analyst James Kelly is sizing things up so far...

  • Merck: Its Ups And Downs Monday, 21 Apr 2008 | 1:17 PM ET
    Merck

    I usually cover pharma earnings from my desk at CNBC HQ in Englewood Cliffs, NJ. But because Merck made a rare offer to interview its Chairman and CEO Dick Clark exclusively this morning I'm out at Merck's idyllic HQ campus in central NJ.

  • Springtime for Pharma: A Big Week Ahead For Earnings Friday, 18 Apr 2008 | 12:01 PM ET
    pharma_generic_earnings.jpg

    The irreverent producers of "Squawk on the Street" who are stationed in the pod next to mine here at CNBC like to call it "Pharmapalooza." They're referring to weeks like the one coming up when nearly every big drug company reports earnings.

  • Pfizer's "Crown Jewel" Lipitor: Has It Lost Its Value? Thursday, 17 Apr 2008 | 12:12 PM ET
    Lipitor

    The world's biggest drug company kicked off pureplay pharma earnings season this morning with disappointing results that look to be dragging down the whole sector. PFE missed Wall Street expectations on revenue and profits.

  • Bobby Murcer as New York Yankees broadcaster

    The world's biggest pharma company is stepping up to the plate again. After the closing bell today PFE announced it's doing a deal worth up to $440 million over time with a baby biotech called Avant Immunotherapeutics.

  • Glaxo, Pozen Become "Headache Free" On Migraine Drug Wednesday, 16 Apr 2008 | 11:21 AM ET
    gsk_logo.jpg

    After navigating what has to be one of the most frustrating paths to Food and Drug Administration approval of a new drug, the small biopharma company Pozen and its big pharma partner GlaxoSmithKline have finally emerged victorious.

  • Dendreon's Secret "Lover" Finally Revealed Tuesday, 15 Apr 2008 | 11:04 AM ET
    dendreon_logo_new.jpg

    It's not Carl Icahn. Earlier this month I blogged about a mysterious institutional investor taking a big stake in the ever-popular biotech Dendreon. DNDN's CFO was quoted as saying the secret admirer was familiar with biotech leading some to speculate it might be the billionaire activist investor who has taken stakes in Biogen-Idec, MedImmune and ImClone, just to name a few.

  • MannKind Being Its Own "Man" About Inhalable Insulin Thursday, 10 Apr 2008 | 12:22 PM ET
    mannkind_logo_1.jpg

    This morning there's a plethora of stuff to blog about: the Takeda-Millennium deal, more commentary about Merck and Schering-Plough and the extent of the Vytorin/Zetia fallout, Genentech's biotech bellweather earnings after the closing bell today, just to name a few.

  • vytorin_logo.jpg

    CNBC and other media outlets have done a significant amount of reporting on cardiologists' reaction to the Vytorin/Zetia study and the effect the ACC panel's opinion might have on the heart doctors' prescription writing.

  • Antigenics Finds That "Russian Roulette" Pays Off Tuesday, 8 Apr 2008 | 10:31 AM ET
    antigenics_logo.jpg

    This morning a little biotech company, Antigenics, announced that Russia has approved its kidney cancer drug Oncophage. It's the first so-called therapeutic cancer vaccine to win full-out approval anywhere in the world.

  • Schering-Plough And The Vytorin-Zetia Backstory Monday, 7 Apr 2008 | 11:31 AM ET
    vytorin_logo.jpg

    The Star-Ledger of New Jersey this weekend did a story that I think provides the best insight and backstory about what happened last week at the highest levels of Schering-Plough.CEO Fred Hassan was in Miami when doctors dropped the bomb on Vytorin and Zetia at the American College of Cardiology meeting.

  • My Merck/Schering-Plough Coverage Draws Your Emails Friday, 4 Apr 2008 | 5:02 PM ET

    This week started out with Merck shares suffering their worst loss since the day the drugmaker recalled Vioxx and Schering-Plough shares posting their worst one-day decline ever. But yesterday, SGP had its biggest percentage gain in eight years and today it's finishing the week as the sector's biggest percentage gainer.